Latest News for BIVI
3:40pm: Small cap wrap BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the final on-treatment visit in its Phase 2 ADDRESS-LC trial evaluating...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating...
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIVI.
U.S. House Trading
No House trades found for BIVI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.